These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 30068361)

  • 1. Targeting the IDO1 pathway in cancer: from bench to bedside.
    Liu M; Wang X; Wang L; Ma X; Gong Z; Zhang S; Li Y
    J Hematol Oncol; 2018 Aug; 11(1):100. PubMed ID: 30068361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
    Kim M; Tomek P
    Front Immunol; 2021; 12():636081. PubMed ID: 33708223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.
    Zhai L; Spranger S; Binder DC; Gritsina G; Lauing KL; Giles FJ; Wainwright DA
    Clin Cancer Res; 2015 Dec; 21(24):5427-33. PubMed ID: 26519060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer.
    Prendergast GC; Malachowski WJ; Mondal A; Scherle P; Muller AJ
    Int Rev Cell Mol Biol; 2018; 336():175-203. PubMed ID: 29413890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor.
    Song X; Si Q; Qi R; Liu W; Li M; Guo M; Wei L; Yao Z
    Front Immunol; 2021; 12():800630. PubMed ID: 35003126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges.
    Peng X; Zhao Z; Liu L; Bai L; Tong R; Yang H; Zhong L
    Drug Des Devel Ther; 2022; 16():2639-2657. PubMed ID: 35965963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tryptophan Catabolism and Cancer Immunotherapy Targeting IDO Mediated Immune Suppression.
    Amobi A; Qian F; Lugade AA; Odunsi K
    Adv Exp Med Biol; 2017; 1036():129-144. PubMed ID: 29275469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression.
    Klar R; Michel S; Schell M; Hinterwimmer L; Zippelius A; Jaschinski F
    Cancer Immunol Immunother; 2020 Jan; 69(1):57-67. PubMed ID: 31802183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization and evolution of vertebrate indoleamine 2, 3-dioxygenases IDOs from monotremes and marsupials.
    Yuasa HJ; Ball HJ; Ho YF; Austin CJ; Whittington CM; Belov K; Maghzal GJ; Jermiin LS; Hunt NH
    Comp Biochem Physiol B Biochem Mol Biol; 2009 Jun; 153(2):137-44. PubMed ID: 19402226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.
    Labadie BW; Bao R; Luke JJ
    Clin Cancer Res; 2019 Mar; 25(5):1462-1471. PubMed ID: 30377198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment.
    Gostner JM; Becker K; Überall F; Fuchs D
    Expert Opin Ther Targets; 2015 May; 19(5):605-15. PubMed ID: 25684107
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Yang D; Zhang S; Fang X; Guo L; Hu N; Guo Z; Li X; Yang S; He JC; Kuang C; Yang Q
    J Med Chem; 2019 Oct; 62(20):9161-9174. PubMed ID: 31580660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
    Cheong JE; Sun L
    Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy.
    Huang Q; Xia J; Wang L; Wang X; Ma X; Deng Q; Lu Y; Kumar M; Zhou Z; Li L; Zeng Z; Young KH; Yi Q; Zhang M; Li Y
    J Hematol Oncol; 2018 Apr; 11(1):58. PubMed ID: 29685162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond.
    Muller AJ; Manfredi MG; Zakharia Y; Prendergast GC
    Semin Immunopathol; 2019 Jan; 41(1):41-48. PubMed ID: 30203227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heme-containing enzymes and inhibitors for tryptophan metabolism.
    Yan D; Lin YW; Tan X
    Metallomics; 2017 Sep; 9(9):1230-1240. PubMed ID: 28650043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of IDO in brain tumor immunotherapy.
    Zhai L; Lauing KL; Chang AL; Dey M; Qian J; Cheng Y; Lesniak MS; Wainwright DA
    J Neurooncol; 2015 Jul; 123(3):395-403. PubMed ID: 25519303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn-AhR-AQP4 signaling pathway.
    Du L; Xing Z; Tao B; Li T; Yang D; Li W; Zheng Y; Kuang C; Yang Q
    Signal Transduct Target Ther; 2020 Feb; 5(1):10. PubMed ID: 32296044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer.
    Liang H; Li T; Fang X; Xing Z; Zhang S; Shi L; Li W; Guo L; Kuang C; Liu H; Yang Q
    Cancer Lett; 2021 Dec; 522():32-43. PubMed ID: 34520819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salinomycin promotes T-cell proliferation by inhibiting the expression and enzymatic activity of immunosuppressive indoleamine-2,3-dioxygenase in human breast cancer cells.
    Ebokaiwe AP; Njoya EM; Sheng Y; Zhang Z; Li S; Zhou Z; Qiang Z; Peng T; Hussein AA; Zhang G; Lu X; Li L; Wang F
    Toxicol Appl Pharmacol; 2020 Oct; 404():115203. PubMed ID: 32822738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.